Highest-materiality recent filing
Contineum reports Q1 net loss $14.5M; cash $246.3M through mid-2029
Cash, cash equivalents and marketable securities of $246.3M as of March 31, 2026; runway through mid-2029.
Contineum PIPE-791 Phase 1b shows safety, numeric pain reduction vs placebo
43-patient crossover trial met primary safety endpoint; no serious AEs, most common TEAEs: headache (n=3), fatigue (n=2).
Contineum reports Q4 2025 net loss of $15.2M; upsizes ATM to $100M; Phase 2 IPF trial dosed
Net loss of $15.2M vs $14.6M in Q4 2024; R&D expenses $12.8M, G&A $4.4M.
Contineum prices upsized $90M public offering at $12.25/share; net proceeds ~$84.2M
7,346,938 shares of Class A common stock sold at $12.25 per share, up from planned $75M.
Contineum Therapeutics starts Phase 2 trial of PIPE-791 for IPF; 324 subjects, completion June 2028
Submitted Phase 2 trial details for PIPE-791 to ClinicalTrials.gov; expects ~324 IPF patients enrolled globally.
Contineum's PIPE-307 Phase 2 RRMS trial misses primary endpoint
Phase 2 VISTA trial of M1 receptor antagonist PIPE-307 did not meet primary or secondary efficacy endpoints.
Contineum reports positive Phase 1b PET data for PIPE-791; confirms target engagement
PIPE-791 achieved high LPA1 brain receptor occupancy in healthy volunteers and PrMS patients.
Contineum Q1 net loss $16.0M, cash $190.7M; files $300M shelf & $75M ATM
Net loss of $16.0M vs $8.4M in Q1 2024; R&D expenses rose 76% to $13.7M.
Contineum Therapeutics appoints Timothy Watkins as CMO and Head of Development
Dr. Watkins appointed Chief Medical Officer effective April 28, 2025, succeeding Dr. Stephen Huhn.
Contineum Q1 2024 cash $117.9M; IPO net proceeds $108M extend runway to 2027
Cash and securities $117.9M at March 31; proforma cash (incl. IPO) $225.9M.
On March 14, 2025, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Diego Miralles, M.D. as a member of its Board, effective March 14, 2025.
On June 21, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Sarah Boyce as a member of its Board, effective June 24, 2024.
On May 20, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Troy Ignelzi as a member of its Board, effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event other_material